Stockscreener 앱 받기
9.02
8.02%
0.67
시간 외 거래:
9.00
-0.02
-0.22%
Surrozen Inc 주식(SRZN)의 최신 뉴스
Surrozen (SRZN) Files for $150 Million Mixed Securities Offering - GuruFocus
Surrozen (SRZN) Files for $150 Million Mixed Securities Offering | SRZN Stock News - GuruFocus
Surrozen Inc Files For Mixed Shelf Of Up To $150 MillionSEC Filing - marketscreener.com
(SRZN) Proactive Strategies - news.stocktradersdaily.com
Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround - Yahoo Finance
Surrozen Holds Successful 2025 Annual Stockholders Meeting - TipRanks
Surrozen secures patent for tissue repair technology By Investing.com - Investing.com Nigeria
Surrozen granted patent from USPTO directed to antibody-based molecules - TipRanks
Surrozen (SRZN) Secures New U.S. Patent for Innovative SWAPTM Te - GuruFocus
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - The Manila Times
Surrozen secures patent for tissue repair technology - Investing.com
Breakthrough Patent: Surrozen's New Wnt Technology Could Transform Tissue Repair Therapeutics - Stock Titan
Surrozen’s (SRZN) Buy Rating Reaffirmed at HC Wainwright - Defense World
Surrozen (SRZN) Receives Continued "Buy" Rating from HC Wainwright | SRZN Stock News - GuruFocus
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Surrozen, Inc. Reports Q1 2025 Financial Results - TipRanks
Surrozen, Inc. Reports First Quarter 2025 Financial Results and Business Update Focused on Ophthalmology Pipeline - Nasdaq
CyberCatch Announces Cybersecurity Solution To Protect Thousands of Drinking Water Systems in U.S. that EPA OIG Report Reveals are at Risk of Cyber Attack with One-Day Disruption Cost of $43.5 Billion - The Globe and Mail
BestGrowthStocks.Com Issues a Comprehensive Analysis of Richtech Robotics - The Globe and Mail
Surrozen’s SZN-8141 ameliorates retinopathy in murine models - BioWorld MedTech
Trend Tracker for (SRZN) - news.stocktradersdaily.com
Surrozen files to sell 5.21M shares of common stock for holders - MSN
When (SRZN) Moves Investors should Listen - news.stocktradersdaily.com
Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise - insights.citeline.com
Surrozen’s Strategic Shift to Ophthalmology and Wnt Pathway Innovations Justify Buy Rating - TipRanks
Insiders Are Loving These 5 Tech and Biotech Stocks - 24/7 Wall St.
Surrozen (SRZN) to Release Earnings on Wednesday - Defense World
Surrozen Focuses on Ophthalmology Amid Financial Challenges - TipRanks
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates - The Manila Times
Surrozen Lands Massive $175M Deal: What This Means for Its Eye Disease Pipeline - Stock Titan
Friday’s Insider Moves: Major Buys in Insurance and Biotech, Sells in Energy - Investing.com Australia
Surrozen sees $11.9 million in stock purchases by Column Group - Investing.com UK
Surrozen Secures $76.4M in Private Placement Deal - TipRanks
Surrozen drops hepatitis drug after Phase I flop - Yahoo
Surrozen shifts focus to eye disease treatments, secures $175M funding - Investing.com India
Surrozen Secures $175Mln In Oversubscribed Private Placement To Advance Ophthalmology Pipeline - Nasdaq
Surrozen to Raise Up to $175 Million in Private Placement; Fine-Tunes Ophthalmology Clinical Programs - MarketScreener
Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund - Endpoints News
Surrozen shifts focus to eye disease treatments, secures $175M funding By Investing.com - Investing.com South Africa
Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development - Nasdaq
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases - The Manila Times
Major Pivot: Surrozen Lands $175M to Develop Breakthrough Eye Disease Treatments - Stock Titan
(SRZN) Trading Advice - Stock Traders Daily
Reviewing Surrozen (NASDAQ:SRZN) & Tenaya Therapeutics (NASDAQ:TNYA) - Defense World
Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld MedTech
(SRZN) On The My Stocks Page - Stock Traders Daily
Week Ahead (Sep.13- 17): FDA Decision, Data Readouts (CALT, ASLN, LIFE…) - RTTNews
Better Warren Buffett Stock: Nu Holdings vs. Bank of America - The Globe and Mail
(SRZN) Trading Signals - Stock Traders Daily
H.C. Wainwright sets $32 target on Surrozen stock with Buy rating - MSN
MicroStrategy Is Rebranding to ‘Strategy.’ Should You Buy, Sell, or Hold MSTR Stock? - The Globe and Mail
How To Trade (SRZN) - Stock Traders Daily
Nektar Therapeutics (NKTR) Stock Drops Amid Biotech Sector Volat - GuruFocus.com
1.11%
1.70%
자본화:
|
볼륨(24시간):